{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T16:17:52Z","timestamp":1789489072079,"version":"build-2803163510"},"reference-count":34,"publisher":"Mattioli1885","issue":"Vol. 21 (2026)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,15]]},"abstract":"<jats:p>Background: Interstitial lung disease (ILD) is a common extramuscular manifestation of idiopathic inflammatory myopathies (IIM). Progressive pulmonary fibrosis (PPF) can develop in a subset of patients with IIM-associated interstitial lung disease (IIM-ILD) and is associated with poor outcomes. This study aimed to evaluate the utility of blood-based biomarkers associated with PPF in patients with IIM-ILD. Methods: We retrospectively reviewed 54 consecutive patients diagnosed with IIM-ILD between January 2018 and December 2023. Patients were categorized as having PPF or not based on 2022 ATS\/ERS\/JRS\/ALAT guideline criteria within 1 year after the diagnosis of IIM-ILD. Lung-specific macromolecules and systemic inflammatory and nutritional indices were calculated using laboratory data obtained at the initial evaluation. These included Krebs von den Lungen-6 (KL-6), surfactant protein-D, C-reactive protein-to-albumin ratio (CAR), neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), aggregate index of systemic inflammation (AISI), fibrosis-4 index, prognostic nutritional index, and geriatric nutritional risk index. Receiver operating characteristic curve analysis was used to determine optimal cutoff values, and logistic regression analyses were performed to identify factors associated with PPF. Results: Of the 54 patients, 32 were classified as having PPF and 22 as not having PPF. The PPF group showed significantly lower hemoglobin levels and significantly higher platelet counts, neutrophil counts, C-reactive protein, and serum KL-6 levels than the non-PPF group. Several systemic inflammatory indices, including CAR, NLR, MLR, PLR, SII, SIRI, and AISI, were significantly higher in the PPF group. AISI showed the highest discriminative ability among the evaluated biomarkers, with an area under the curve of 0.786 and an optimal cutoff value of 278. In multivariable logistic regression analysis, serum KL-6 \u2265626 U\/mL and AISI \u2265278 were independently associated with PPF, with adjusted odds ratios of 6.480 (95% confidence interval [CI]: 1.440\u201329.200; p = 0.015) and 9.940 (95% CI: 2.260\u201343.600; p = 0.002), respectively. Conclusions: AISI and serum KL-6 may serve as accessible, non-invasive blood-based biomarkers associated with fibrotic progression in patients with IIM-ILD.<\/jats:p>","DOI":"10.5826\/mrm.2026.1112","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:58:37Z","timestamp":1789487917000},"page":"1112","source":"Crossref","is-referenced-by-count":0,"title":["Blood-based biomarkers associated with progressive pulmonary fibrosis in idiopathic inflammatory myositis-associated interstitial lung disease: A retrospective cohort study from a respiratory center"],"prefix":"10.5826","volume":"21","author":[{"given":"Mayuko","family":"Ishiwari","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Medical University Hospital, Tokyo,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Kono","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Medical University Hospital, Tokyo,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Medical University Hospital, Tokyo,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Kikuchi","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Medical University Hospital, Tokyo,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Kogami","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Medical University Hospital, Tokyo,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Okuma","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Medical University Hospital, Tokyo,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Abe","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Medical University Hospital, Tokyo,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27750","reference":[{"key":"10.5826\/mrm.2026.1112_ref1","doi-asserted-by":"crossref","unstructured":"1. Kannappan R, Kumar R, Cichelli K, Brent LH. A review of myositis-associated interstitial lung disease. J Clin Med 2024;13:4055.","DOI":"10.3390\/jcm13144055"},{"key":"10.5826\/mrm.2026.1112_ref2","doi-asserted-by":"crossref","unstructured":"2. Hallowell RW, Danoff SK. Diagnosis and management of myositis-associated lung disease. Chest 2023;163:1476-91.","DOI":"10.1016\/j.chest.2023.01.031"},{"key":"10.5826\/mrm.2026.1112_ref3","doi-asserted-by":"crossref","unstructured":"3. Wang H, Wang Y, Sun D, Yu S, Du X, Ye Q. Progressive pulmonary fibrosis in myositis-positive interstitial pneumonia: a retrospective cohort study. Front Med (Lausanne) 2023;10:1325082.","DOI":"10.3389\/fmed.2023.1325082"},{"key":"10.5826\/mrm.2026.1112_ref4","doi-asserted-by":"crossref","unstructured":"4. Zhu L, Wu S, Zong C, Chen Y, Sun C, Zhang Y, et al. A serum biomarker-based index for predicting progressive pulmonary fibrosis in patients with anti-synthetase syndrome: the LOCCM index. Respir Res 2025;26:329.","DOI":"10.1186\/s12931-025-03414-3"},{"key":"10.5826\/mrm.2026.1112_ref5","unstructured":"5. Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis: an update and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med 2022;205:e18-47."},{"key":"10.5826\/mrm.2026.1112_ref6","doi-asserted-by":"crossref","unstructured":"6. Molina-Molina M, Castellv\u00ed I, Valenzuela C, Ramirez J, Portal JAR, Franquet T, et al. Management of progressive pulmonary fibrosis associated with connective tissue disease. Expert Rev Respir Med 2022;16:765-74.","DOI":"10.1080\/17476348.2022.2107508"},{"key":"10.5826\/mrm.2026.1112_ref7","doi-asserted-by":"crossref","unstructured":"7. Templeton AJ, McNamara MG, \u0160eruga B, Vera-Badillo FE, Aneja P, Oca\u00f1a A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014;106:dju124.","DOI":"10.1093\/jnci\/dju124"},{"key":"10.5826\/mrm.2026.1112_ref8","doi-asserted-by":"crossref","unstructured":"8. Fairclough E, Cairns E, Hamilton J, Kelly C. Evaluation of a modified early warning system for acute medical admissions and comparison with C-reactive protein\/albumin ratio as a predictor of patient outcome. Clin Med (Lond) 2009;9:30-3.","DOI":"10.7861\/clinmedicine.9-1-30"},{"key":"10.5826\/mrm.2026.1112_ref9","doi-asserted-by":"crossref","unstructured":"9. Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer: a retrospective review. BMC Cancer 2013;13:158.","DOI":"10.1186\/1471-2407-13-158"},{"key":"10.5826\/mrm.2026.1112_ref10","doi-asserted-by":"crossref","unstructured":"10. Jakubowska K, Koda M, Grudzi\u0144ska M, Ka\u0144czuga-Koda L, Famulski W. Monocyte-to-lymphocyte ratio as a prognostic factor in peripheral whole blood samples of colorectal cancer patients. World J Gastroenterol 2020;26:4639-55.","DOI":"10.3748\/wjg.v26.i31.4639"},{"key":"10.5826\/mrm.2026.1112_ref11","doi-asserted-by":"crossref","unstructured":"11. Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, et al. Prognostic role of platelet-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2014;23:1204-12.","DOI":"10.1158\/1055-9965.EPI-14-0146"},{"key":"10.5826\/mrm.2026.1112_ref12","doi-asserted-by":"crossref","unstructured":"12. Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res 2014;20:6212-22.","DOI":"10.1158\/1078-0432.CCR-14-0442"},{"key":"10.5826\/mrm.2026.1112_ref13","doi-asserted-by":"crossref","unstructured":"13. Qi Q, Zhuang L, Shen Y, Geng Y, Yu S, Chen H, et al. A novel systemic inflammation response index predicts the prognosis of patients with pancreatic cancer after chemotherapy. Cancer 2016;122:2158-67.","DOI":"10.1002\/cncr.30057"},{"key":"10.5826\/mrm.2026.1112_ref14","doi-asserted-by":"crossref","unstructured":"14. Zinellu A, Collu C, Nasser M, Paliogiannis P, Mellino S, Zinellu E, et al. The aggregate index of systemic inflammation: a novel prognostic biomarker in idiopathic pulmonary fibrosis. J Clin Med 2021;10:4134.","DOI":"10.3390\/jcm10184134"},{"key":"10.5826\/mrm.2026.1112_ref15","unstructured":"15. Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi 1984;85:1001-5."},{"key":"10.5826\/mrm.2026.1112_ref16","doi-asserted-by":"crossref","unstructured":"16. Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent JP, Nicolis I, et al. Geriatric nutritional risk index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr 2005;82:777-83.","DOI":"10.1093\/ajcn\/82.4.777"},{"key":"10.5826\/mrm.2026.1112_ref17","doi-asserted-by":"crossref","unstructured":"17. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 2006;43:1317-25.","DOI":"10.1002\/hep.21178"},{"key":"10.5826\/mrm.2026.1112_ref18","doi-asserted-by":"crossref","unstructured":"18. Yuan W, Zhou X, Yang Y, Zhang S, He X, Ji J. Associated factors in the development of rapidly progressive interstitial lung disease in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis. Front Immunol 2025;16:1628928.","DOI":"10.3389\/fimmu.2025.1628928"},{"key":"10.5826\/mrm.2026.1112_ref19","doi-asserted-by":"crossref","unstructured":"19. Lundberg IE, Tj\u00e4rnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. European league against rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol 2017;69:2271-82.","DOI":"10.1002\/art.40320"},{"key":"10.5826\/mrm.2026.1112_ref20","doi-asserted-by":"crossref","unstructured":"20. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975;292:344-7.","DOI":"10.1056\/NEJM197502132920706"},{"key":"10.5826\/mrm.2026.1112_ref21","doi-asserted-by":"crossref","unstructured":"21. Cavagna L, Trallero-Aragua\u0301s E, Meloni F, Cavazzana I, Rojas-Serrano J, Feist E, et al. Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course. J Clin Med 2019;8:2013.","DOI":"10.3390\/jcm8112013"},{"key":"10.5826\/mrm.2026.1112_ref22","doi-asserted-by":"crossref","unstructured":"22. Lega JC, Reynaud Q, Belot A, Fabien N, Durieu I, Cottin V. Idiopathic inflammatory myopathies and the lung. Eur Respir Rev 2015;24:216-38.","DOI":"10.1183\/16000617.00002015"},{"key":"10.5826\/mrm.2026.1112_ref23","doi-asserted-by":"crossref","unstructured":"23. Ryerson CJ, Adegunsoye A, Piciucchi S, Hariri LP, Khor YH, Wijsenbeek MS, et al. Update of the international multidisciplinary classification of the interstitial pneumonias: an ERS\/ATS statement. Eur Respir J 2025;66:2500158.","DOI":"10.1183\/13993003.00158-2025"},{"key":"10.5826\/mrm.2026.1112_ref24","doi-asserted-by":"crossref","unstructured":"24. Kanda Y. Investigation of the freely available easy-to-use software EZR for medical statistics. Bone Marrow Transplant 2013;48:452-8.","DOI":"10.1038\/bmt.2012.244"},{"key":"10.5826\/mrm.2026.1112_ref25","doi-asserted-by":"crossref","unstructured":"25. Mochizuka Y, Suzuki Y, Kono M, Hasegawa H, Hashimoto D, Yokomura K, et al. Geriatric nutritional risk index is a predictor of tolerability of antifibrotic therapy and mortality risk in patients with idiopathic pulmonary fibrosis. Respirology 2023;28:775-83.","DOI":"10.1111\/resp.14523"},{"key":"10.5826\/mrm.2026.1112_ref26","doi-asserted-by":"crossref","unstructured":"26. Ishiwari M, Kono Y, Togashi Y, Kobayashi K, Kikuchi R, Kogami M, et al. Nutritional assessments as predictors of prognosis after long-term oxygen therapy in patients with idiopathic pulmonary fibrosis. Respir Investig 2025;63:1204-9.","DOI":"10.1016\/j.resinv.2025.09.019"},{"key":"10.5826\/mrm.2026.1112_ref27","doi-asserted-by":"crossref","unstructured":"27. Li M, Zhao X, Liu B, Zhao Y, Li X, Ma Z, et al. Predictors of rapidly progressive interstitial lung disease and prognosis in Chinese patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Front Immunol 2023;14:1209282.","DOI":"10.3389\/fimmu.2023.1209282"},{"key":"10.5826\/mrm.2026.1112_ref28","doi-asserted-by":"crossref","unstructured":"28. Hosseninia S, Ghobadi H, Garjani K, Hosseini SAH, Aslani MR. Aggregate index of systemic inflammation in admission as a reliable predictor of mortality in COPD patients with COVID-19. BMC Pulm Med 2023;23:107.","DOI":"10.1186\/s12890-023-02397-5"},{"key":"10.5826\/mrm.2026.1112_ref29","doi-asserted-by":"crossref","unstructured":"29. Ma X, Chen S, Yang H, Zhang J, Jin W, Yan C, et al. The clinical value of lymphocyte percentages and monocyte-to-lymphocyte ratios in the differential diagnosis of immune-mediated necrotizing myopathy and dermatomyositis. Front Neurol 2025;16:1581206.","DOI":"10.3389\/fneur.2025.1581206"},{"key":"10.5826\/mrm.2026.1112_ref30","doi-asserted-by":"crossref","unstructured":"30. Yi M, Liu M, Zhu Z, Li H, Shu J, Guo Y, et al. Incidence and influencing factors of progressive pulmonary fibrosis in connective tissue disease-associated interstitial lung disease: a systematic review and meta-analysis. Front Immunol 2026;17:1758437.","DOI":"10.3389\/fimmu.2026.1758437"},{"key":"10.5826\/mrm.2026.1112_ref31","doi-asserted-by":"crossref","unstructured":"31. Lee J, Kim K, Jo YS. Comparison of the diagnostic criteria for progressive pulmonary fibrosis in connective tissue disease-related interstitial lung disease. Respir Med 2023;212:107242.","DOI":"10.1016\/j.rmed.2023.107242"},{"key":"10.5826\/mrm.2026.1112_ref32","doi-asserted-by":"crossref","unstructured":"32. Hu C, Wu C, Yang E, Huang H, Xu D, Hou Y, et al. Serum KL-6 is associated with the severity of interstitial lung disease in Chinese patients with polymyositis and dermatomyositis. Clin Rheumatol 2019;38:2181-7.","DOI":"10.1007\/s10067-019-04501-9"},{"key":"10.5826\/mrm.2026.1112_ref33","doi-asserted-by":"crossref","unstructured":"33. Kaieda S, Gono T, Masui K, Nishina N, Sato S, Kuwana M, et al. Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease. PLoS One 2020;15:e0234523.","DOI":"10.1371\/journal.pone.0234523"},{"key":"10.5826\/mrm.2026.1112_ref34","doi-asserted-by":"crossref","unstructured":"34. Faria MSMS, Yoshida A, Mugii N, Inaoka PT, Matsushita T, Gono T, et al. Different phenotypic manifestations between Brazilian and Japanese anti-MDA5 antibody-positive dermatomyositis: an international tricentric longitudinal study. Clin Exp Rheumatol 2025;43:193-201.","DOI":"10.55563\/clinexprheumatol\/9s7djz"}],"container-title":["Multidisciplinary Respiratory Medicine"],"original-title":[],"link":[{"URL":"https:\/\/mrmjournal.org\/index.php\/mrm\/article\/download\/1112\/1606","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/mrmjournal.org\/index.php\/mrm\/article\/download\/1112\/1606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:58:51Z","timestamp":1789487931000},"score":1,"resource":{"primary":{"URL":"https:\/\/mrmjournal.org\/index.php\/mrm\/article\/view\/1112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":34,"journal-issue":{"issue":"Vol. 21 (2026)"},"URL":"https:\/\/doi.org\/10.5826\/mrm.2026.1112","relation":{"has-manifestation":[{"id-type":"other","id":"1-44-1112-g1606","asserted-by":"subject"}],"is-part-of":[{"id-type":"other","id":"1-44","asserted-by":"subject"}]},"ISSN":["2049-6958","1828-695X"],"issn-type":[{"value":"2049-6958","type":"electronic"},{"value":"1828-695X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,15]]}}}